BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23862120)

  • 1. Prevention and Inhibition of TC-1 Cell Growth in Tumor Bearing Mice by HPV16 E7 Protein in Fusion with Shiga Toxin B-Subunit from shigella dysenteriae.
    Sadraeian M; Khoshnood Mansoorkhani MJ; Mohkam M; Rasoul-Amini S; Hesaraki M; Ghasemi Y
    Cell J; 2013; 15(2):176-81. PubMed ID: 23862120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of antitumor immunity against cervical cancer by protein HPV-16 E7 in fusion with ricin B chain in tumor-bearing mice.
    Sadraeian M; Rasoul-Amini S; Mansoorkhani MJ; Mohkam M; Ghoshoon MB; Ghasemi Y
    Int J Gynecol Cancer; 2013 Jun; 23(5):809-14. PubMed ID: 23574882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization of protein HPV16 E7 in fusion with mouse HSP70 inhibits the growth of TC-1 cells in tumor bearing mice.
    Li YL; Liu J; Liu JN; Zhang J
    Vaccine; 2011 Aug; 29(35):5959-62. PubMed ID: 21722685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
    Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
    Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.
    Zhou L; Zhu T; Ye X; Yang L; Wang B; Liang X; Lu L; Tsao YP; Chen SL; Li J; Xiao X
    Hum Gene Ther; 2010 Jan; 21(1):109-19. PubMed ID: 19715402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification in media composition to obtain secretory production of STxB-based vaccines using Escherichia coli.
    Sadraeian M; Ghoshoon MB; Mohkam M; Karimi Z; Rasoul-Amini S; Ghasemi Y
    Virol Sin; 2013 Feb; 28(1):43-8. PubMed ID: 23329470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
    Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
    Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with mutant HPV16 E7 protein inhibits the growth of TC-1 cells in tumor-bearing mice.
    Li YL; Ma ZL; Zhao Y; Zhang J
    Oncol Lett; 2015 Apr; 9(4):1851-1856. PubMed ID: 25789055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fungal mannosylation enhances human papillomavirus 16 E7 therapeutic immunity against TC-1 tumors.
    Wang Z; Wei C; Zhang Y; Wang W; Zhou Z; Xiao G
    Oncol Rep; 2018 Jan; 39(1):425-432. PubMed ID: 29115562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity.
    Vingert B; Adotevi O; Patin D; Jung S; Shrikant P; Freyburger L; Eppolito C; Sapoznikov A; Amessou M; Quintin-Colonna F; Fridman WH; Johannes L; Tartour E
    Eur J Immunol; 2006 May; 36(5):1124-35. PubMed ID: 16568496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
    Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
    Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization of mice by the co-administration of codon-optimized HPV16 E7 and lL12 genes against HPV16-associated cervical cancer.
    Ajorloo M; Alamdary A; Soleimanjahi H; El Boulani A; Khanizadeh S; Nikoo HR
    Microb Pathog; 2019 Jul; 132():20-25. PubMed ID: 31004722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity.
    Adotevi O; Vingert B; Freyburger L; Shrikant P; Lone YC; Quintin-Colonna F; Haicheur N; Amessou M; Herbelin A; Langlade-Demoyen P; Fridman WH; Lemonnier F; Johannes L; Tartour E
    J Immunol; 2007 Sep; 179(5):3371-9. PubMed ID: 17709554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
    Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
    Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7.
    Chu NR; Wu HB; Wu TC; Boux LJ; Mizzen LA; Siegel MI
    Cell Stress Chaperones; 2000 Nov; 5(5):401-5. PubMed ID: 11189443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The contribution of NT-gp96 as an adjuvant for increasing HPV16 E7-specific immunity in C57BL /6 mouse model.
    Mohit E; Bolhassani A; Zahedifard F; Taslimi Y; Rafati S
    Scand J Immunol; 2012 Jan; 75(1):27-37. PubMed ID: 21916914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model.
    Li J; Sun Y; Garen A
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16232-6. PubMed ID: 12446839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.